BALAXI PHARMACEUTICALS LIMITED Share Price & Analysis
Price Chart
Fundamentals
Strengths
Concerns
- Low capital efficiency (ROCE 3.5%)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
BALAXI · as of Jun 2026
| Category | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 66.86% | 65.99% | 65.99% | 65.99% | 65.99% | 65.99% |
| FII | 17.21% | 16.88% | 16.48% | 16.48% | 16.02% | 8.87% |
| DII | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 15.91% | 17.11% | 17.50% | 17.50% | 17.96% | 25.12% |
Latest News
All newsBalaxi Pharma gets WHO-GMP certification for manufacturing facility
*Balaxi Pharma gets WHO-GMP certification for manufacturing facility.* This certification enables the company to export generic drugs to international markets regulated by the WHO. The facility clearance is a key step toward global market expansion. **No financial figures** were disclosed in the filing. 📊 *STOCKS:* $BALAXI | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Regulatory
Balaxi Pharmaceuticals updates share transfer re-lodgement report
*Balaxi Pharmaceuticals updates RTA report for re-lodgement of physical share transfer requests.* This covers pending transfers for the period ended September 2026. No financial or operational impact is indicated. The filing is a procedural compliance update. 📊 *STOCKS:* $BALAXI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporate
Balaxi Pharmaceuticals publishes statutory notice in newspaper
*Balaxi Pharmaceuticals publishes statutory notice in newspaper.* This is a routine compliance filing with no operational or financial impact. Such notices are standard for corporate disclosures under regulatory requirements. No material development is indicated. 📊 *STOCKS:* $BALAXI | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma